Colon capsule endoscopy and its effectiveness in the diagnosis and management of colorectal neoplastic lesions

Sebastian Manuel Milluzzo, Alessandra Bizzotto, Paola Cesaro, Cristiano Spada

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Colorectal cancer (CRC) represents a major cause of morbidity and mortality in Western countries. Though colonoscopy is the benchmark for CRC diagnosis and management, other alternatives have been proposed. Colon capsule endoscopy (CCE) was first introduced in 2006 as a non-invasive painless technology that utilizes an ingestible, wireless, and disposable capsule to explore the colon, without sedation or air insufflation. Areas covered: To date, the European Society of Gastrointestinal Endoscopy (ESGE) guidelines consider CCE as an option for average-risk colorectal cancer screening patients and in patients with contraindications or unwilling to undergo colonoscopy and/or with an incomplete colonoscopy. Furthermore, Japan's Pharmaceuticals and Medical Devices Agency (JPMDA) and Food and Drug Administration (FDA) approved the use of CCE in patients unwilling or unable to undergo colonoscopy. Expert commentary: CCE accuracy is nearly comparable to conventional colonoscopy for CRC and significant polyps. Moreover, in the setting of incomplete colonoscopy, CCE was demonstrated to have a higher diagnostic yield for significant polyps and to be better tolerated than CTC. However, the use of CCE is still limited. The lesson coming out is that we should explore new populations that are suitable for colon capsules and for which the colon capsule can be an advantage.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalExpert Review of Anticancer Therapy
DOIs
Publication statusE-pub ahead of print - Oct 25 2018

Fingerprint

Capsule Endoscopy
Colon
Colonoscopy
Colorectal Neoplasms
Capsules
Polyps
Benchmarking
Insufflation
United States Food and Drug Administration
Early Detection of Cancer
Japan
Air
Guidelines
Technology
Morbidity
Equipment and Supplies

Cite this

Colon capsule endoscopy and its effectiveness in the diagnosis and management of colorectal neoplastic lesions. / Milluzzo, Sebastian Manuel; Bizzotto, Alessandra; Cesaro, Paola; Spada, Cristiano.

In: Expert Review of Anticancer Therapy, 25.10.2018, p. 1-10.

Research output: Contribution to journalArticle

@article{2291605a23b14be196a332e44de65549,
title = "Colon capsule endoscopy and its effectiveness in the diagnosis and management of colorectal neoplastic lesions",
abstract = "INTRODUCTION: Colorectal cancer (CRC) represents a major cause of morbidity and mortality in Western countries. Though colonoscopy is the benchmark for CRC diagnosis and management, other alternatives have been proposed. Colon capsule endoscopy (CCE) was first introduced in 2006 as a non-invasive painless technology that utilizes an ingestible, wireless, and disposable capsule to explore the colon, without sedation or air insufflation. Areas covered: To date, the European Society of Gastrointestinal Endoscopy (ESGE) guidelines consider CCE as an option for average-risk colorectal cancer screening patients and in patients with contraindications or unwilling to undergo colonoscopy and/or with an incomplete colonoscopy. Furthermore, Japan's Pharmaceuticals and Medical Devices Agency (JPMDA) and Food and Drug Administration (FDA) approved the use of CCE in patients unwilling or unable to undergo colonoscopy. Expert commentary: CCE accuracy is nearly comparable to conventional colonoscopy for CRC and significant polyps. Moreover, in the setting of incomplete colonoscopy, CCE was demonstrated to have a higher diagnostic yield for significant polyps and to be better tolerated than CTC. However, the use of CCE is still limited. The lesson coming out is that we should explore new populations that are suitable for colon capsules and for which the colon capsule can be an advantage.",
author = "Milluzzo, {Sebastian Manuel} and Alessandra Bizzotto and Paola Cesaro and Cristiano Spada",
year = "2018",
month = "10",
day = "25",
doi = "10.1080/14737140.2019.1538798",
language = "English",
pages = "1--10",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Colon capsule endoscopy and its effectiveness in the diagnosis and management of colorectal neoplastic lesions

AU - Milluzzo, Sebastian Manuel

AU - Bizzotto, Alessandra

AU - Cesaro, Paola

AU - Spada, Cristiano

PY - 2018/10/25

Y1 - 2018/10/25

N2 - INTRODUCTION: Colorectal cancer (CRC) represents a major cause of morbidity and mortality in Western countries. Though colonoscopy is the benchmark for CRC diagnosis and management, other alternatives have been proposed. Colon capsule endoscopy (CCE) was first introduced in 2006 as a non-invasive painless technology that utilizes an ingestible, wireless, and disposable capsule to explore the colon, without sedation or air insufflation. Areas covered: To date, the European Society of Gastrointestinal Endoscopy (ESGE) guidelines consider CCE as an option for average-risk colorectal cancer screening patients and in patients with contraindications or unwilling to undergo colonoscopy and/or with an incomplete colonoscopy. Furthermore, Japan's Pharmaceuticals and Medical Devices Agency (JPMDA) and Food and Drug Administration (FDA) approved the use of CCE in patients unwilling or unable to undergo colonoscopy. Expert commentary: CCE accuracy is nearly comparable to conventional colonoscopy for CRC and significant polyps. Moreover, in the setting of incomplete colonoscopy, CCE was demonstrated to have a higher diagnostic yield for significant polyps and to be better tolerated than CTC. However, the use of CCE is still limited. The lesson coming out is that we should explore new populations that are suitable for colon capsules and for which the colon capsule can be an advantage.

AB - INTRODUCTION: Colorectal cancer (CRC) represents a major cause of morbidity and mortality in Western countries. Though colonoscopy is the benchmark for CRC diagnosis and management, other alternatives have been proposed. Colon capsule endoscopy (CCE) was first introduced in 2006 as a non-invasive painless technology that utilizes an ingestible, wireless, and disposable capsule to explore the colon, without sedation or air insufflation. Areas covered: To date, the European Society of Gastrointestinal Endoscopy (ESGE) guidelines consider CCE as an option for average-risk colorectal cancer screening patients and in patients with contraindications or unwilling to undergo colonoscopy and/or with an incomplete colonoscopy. Furthermore, Japan's Pharmaceuticals and Medical Devices Agency (JPMDA) and Food and Drug Administration (FDA) approved the use of CCE in patients unwilling or unable to undergo colonoscopy. Expert commentary: CCE accuracy is nearly comparable to conventional colonoscopy for CRC and significant polyps. Moreover, in the setting of incomplete colonoscopy, CCE was demonstrated to have a higher diagnostic yield for significant polyps and to be better tolerated than CTC. However, the use of CCE is still limited. The lesson coming out is that we should explore new populations that are suitable for colon capsules and for which the colon capsule can be an advantage.

U2 - 10.1080/14737140.2019.1538798

DO - 10.1080/14737140.2019.1538798

M3 - Article

C2 - 30354507

SP - 1

EP - 10

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

ER -